Key Takeaways PacBio beat first-quarter estimates with higher margins and a narrower adjusted operating loss. PACB's Revio and Vega systems drove adoption across research, clinical, and academic markets. PacBio targets $45 to $50 million in annual cost savings via restructuring by the end of 2025.Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by decent first-quarter results, is expected to contribute fu ...

Pacific Biosciences of California (PACB) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Todd Friedman - Senior Director, FP&A and Investor RelationsChristian Henry - President & Chief Executive OfficerTom Nikic - Managing Director, Equity ResearchJim Gibson - CFOHarrison Parsons - Equity Research AssociateWilliam Ruby - Equity Research Associate Conference Call Participants Jake Titleman - AnalystJack Meehan - Equity Research AnalystAlex Vukasin - VP Healthcare Equity Research AnalystDa ...